Customized Cell Culture Solutions
Our product line includes:
Contract manufacturing (OEM) of sterile liquids and powder formulations
Custom-designed media for upstream bioprocessing applications (biologics, biosimilar, vaccines)
Standard products & modifications thereof
Specialty waters (WFI USP/EP, nuclease free waters, etc)
Specialty buffers & salt solutions for upstream & downstream bioprocessing
Production platform media for CHO, Hybridoma and Insect Cells
Serum-free and Animal Component Free (ACF)
Standard and Animal Origin media (AO) media for primary and stems cells
Supplements and auxiliary reagents
In addition to the broad range of cell culture products, we can offer the highest degree of flexibility and customization in a short period of time.
Benefit from the options:
Modifications of standard products
New products according to customers recipes
Variable liquid batch sizes starting from 5L up to 5000L; in bottle (50ml-5000ml) and 2D/3D bags (1L-1000L)
Variable packaging sizes and packaging systems (PET / glass bottles, sterile 2D/3D bags, customized tubing systems)
Sterilization through sterile filtration (0.22µm) or hot air/vapor sterilization
Media and buffer powder production from 2kg up to 800kg for pilot scale, scale up and production.
Flexibility and Capacity
Variable batch sizes
Variable packaging sizes and systems
Liquid: sterile PET / glass bottles, bags, customized tubing systems, according to custom specifications. Powder: Barrels, drums and cans
Customer-designed media
Modifications of standard products. New products according to customers recipes
Customized products
can be delivered within 6 to 8 weeks after the order has been placed, including Quality Control.
CHO Cell Lines and ACF Media
Available cell lines for biosimilar production at different stages of development as well as complete ready-to-go processes for commercial manufacturing (selection):
Adalimumab — TNFa Mab | Cell Line (rheumatoid arthritis, Crohn’s) USP & DSP
Bevacizumab — VEGF Mab | Cell Line (colorectal cancer) USP & DSP
Cetuximab — EGF receptor Mab | Cell Line (colorectal cancer) & USP
Denosumab — RANKL IgG | Cell Line (osteoporosis, colorectal cancer) USP
DPO — Darbepoetin alpha | Cell-Line & USP & DSP (Anemia)
Eculizumab — Complement C5 Mab | Cell Line USP
EPO — Epoetin alpha (Anemia) | Cell-Line & USP & DSP
Etanercept — TNFa receptor IgG | Cell Line (chronical arthritis, psoriasis) USP & DSP
FSH — follicle stimulating hormon | Cell-Line & USP & DSP (Infertility); also hCG & LH
INFb — Interferon beta 1a | Cell-Line & USP & DSP (MS)
Ipilimumab — CTLA-4 IgG1 | Cell Line (metastatic melanoma) USP
Omalizumab — IgE Mab | Cell Line (persistent allergic asthma) USP
Rituximab — CD20 Mab | Cell Line (rheumatoid arthritis, lymphoma) USP & DSP
Trastuzumab — HER2 Mab | Cell Line (mammacarcinom) USP & DSP
All cell lines are provided by Eugenex Biotechnologies GmbH.
Use the Benefits of CHO Production Media
BioConcept’s CHO Media is Animal Component Free (ACF) and in accordance with strict quality guidelines EMA/410/01. BioConcept holds a certificate for every single component used in its media series to guarantee the high quality of the media. The media is also protein and protein hydrolysates free. Altogether it helps the customer to produce an untainted and exceptional final product for therapeutic use.
CHOSI cells cultured in our media have shown fast growth and a much higher cell density compared to other media. This results in final product titers at the end of the fed-batch cycle. The higher viability in the stationary phase shows that the glycosylation is superior.
“Our customized products require a lot of know-how, which Bioconcept has offered in a straightforward way. Bioconcept is also a good partner for our up- and downstream process and supports us with the necessary media and buffers.”
Frank S.
Manufacturing to the Highest Standards
BioConcept currently operates two segregated liquid media production facilities (Liquid I and Liquid II) and two segregated powder media production facilities (Powder I and Powder II). Both liquid facilities are equipped with qualified ISO 5 (GMP A) cleanrooms.
Our facilities are in accordance with GMP guidelines, e.g. air and water preparation facility, calibrated and qualified instruments, validated processes, fully integrated Standard Operating Procedures (SOPs) and comprehensive documentation of production. The state-of-the-art air processing system provides us with the optimal conditions required for sterile liquid production.
For the preparation of the bottles, we use a cleanroom robot to minimize the particle count. All further steps, including sealing and labelling, are also performed automatically.
In summary, the plant has been designed to create an environment that upholds the highest degree of sterility possible, thereby ensuring a sterile final product.
Who we are
Established in 1978, BioConcept is a privately owned company with more than 45 years of experience in serving the life science and biopharma community.
We strive to combine this experience with an innovative spirit to support our customers’ needs with the best possible solutions. To do so, BioConcept establishes close relationships with its customers to be able to respond to their stringent requirements. To guarantee that our products are of the highest standard, BioConcept has been manufacturing products within a certified quality management system (ISO 9001) since 1995. The current ISO standard is 9001:2015. Our products are produced according to GMP guidelines.
With our new facilities, and our convenient location near Basel airport at the junction of Switzerland, Germany, and France, we aspire to expand further internationally. We shall continue to listen to the needs of the market and be flexible when meeting their objectives.
